Physician profile
Sang Jho
NPI 1053555961
$8,478.83
in general payments reported to CMS, 2019-2025
13 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.24 · 2020: $136 · 2021: $53.72 · 2023: $364 · 2024: $7,649 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,618 · Education: $2,500 · Food and Beverage: $2,072 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,618.19 |
| Education | $2,500.00 |
| Food and Beverage | $2,071.86 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,988.13 | 2024 | |
| Davol INC. | $628.68 | 2023-2025 | Phasix Mesh |
| Kerecis Limited | $235.64 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Atricure, INC. | $150.91 | 2023 | |
| Amarin Pharma, INC. | $117.75 | 2020 | |
| W. L. Gore & Associates, INC. | $103.25 | 2024 | Gore Synecor Biomaterial |
| Tela Bio, INC. | $90.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $57.01 | 2021-2023 | Xarelto |
| Melinta Therapeutics, LLC | $31.86 | 2023 | Vabomere, Kimyrsa |
| Abbvie INC. | $23.32 | 2024 | |
| Amgen INC. | $18.47 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $18.33 | 2020 | |
| Lifenet Health | $15.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sang Jho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.